Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

Hepatology

Volumn 63, Issue 5, 2016, Pages 1481-1492

  Papatheodoridis, George ^a   Vlachogiannakos, Ioannis ^a   Cholongitas, Evangelos ^b   Wursthorn, Karsten ^c   Thomadakis, Christos ^a   Touloumi, Giota ^a   Petersen, Jörg ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; VIRUS DNA;

ARTICLE; CHRONIC HEPATITIS B; CONSOLIDATION CHEMOTHERAPY; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REMISSION; SEROCONVERSION; SYSTEMATIC REVIEW; BLOOD; COMPLICATION; HEPATITIS B, CHRONIC; LIVER CIRRHOSIS; ORAL DRUG ADMINISTRATION; PROBABILITY; RECURRENT DISEASE; VIROLOGY;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; PROBABILITY; RECURRENCE;

EID: 84959470623     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28438     Document Type: Article

References (41)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
3. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008;8:167-178.
4. Papatheodoridis GV. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 2013;33(Suppl. 1):151-156.
5. Chang TT, Lai CL, Kew YS, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
6. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
7. Petersen J, Dandri M. Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Liver Int 2015;35(Suppl. 1):114-120.
8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
9. Sterne JAC, Higgins JPT, Reeves BC; on behalf of the development group for ACROBAT-NRS. A Cochrane Risk of Bias Assessment Tool: For Non-Randomized Studies of Interventions (ACROBAT-NRSI), version 1.0.0, September 24, 2014. http://www.riskofbias.info. Accessed July 2015.
10. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-438.
11. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Morikawa H, Jomura H, et al. Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. Hepatol Res 2008;38:954-959.
12. Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol 2009;45:114-118.
13. Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009;104:1940-1946.
14. Wang L, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat 2010;17:298-304.
15. Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol 2010;45:75-81.
16. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48:22-26.
17. Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011;26:456-460.
18. Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, et al. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2011;17:261-267.
19. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249-1257.
20. Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-870.
21. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-636.
22. Ha M, Zhang G, Diao S, Lin M, Sun L, She H, et al. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol 2012;157:285-290.
23. Song MJ, Song dS, Kim HY, Yoo SH, Bae SH, Choi JY, et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012;18:6277-6283.
24. He D, Guo S, Chen W, Chen X, Yan G, Wang J, et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis 2013;13:458.
25. Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, et al. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol 2013;19:300-304.
26. Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-1896.
27. Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, et al. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol 2013;85:34-42.
28. Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Munoz AE, Adrover R, et al. Relapse rates in chronic hepatitis B naive patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014;21:590-596.
29. Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, et al. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis 2014;14:439.
30. Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014;40:804-810.
31. He D, Guo S, Zhu P, Tao S, Li M, Huang H, et al. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect 2014;20:O687-O693.
32. Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515-522.
33. Jiang JN, Huang ZL, He LX, Huang YH, Su MH, Xie R, et al. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol 2014;49:323-328.
34. Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2014;64:667-672.
35. Vale CL, Tierney JF, Stewart LA. Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol 2002;31:107-111.
36. Barrett JK, Farewell VT, Siannis F, Tierney J, Higgins JP. Two-stage meta-analysis of survival data from individual participants using percentile ratios. Stat Med 2012;31:4296-4308.
37. Reijnders JG, Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? Hepatology 2013;58:1885-1887.
38. Hadziyannis S, Liaw YF. Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B. Gut 2015;64:1005-1006.
39. Liaw Y-F, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-561.
40. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass D, et al. Stopping tenofovir disoproxil fumarate (TDF) treatment after long-term virologic suppression in HBeAg-negative CHB: week 48 interim results from an ongoing randomized, controlled trial (FINITE CHB). J Hepatol 2015;62:S253.
41. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland; 2015.